Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

6 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Follow-Up - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 9/3/20 - 1 formulario, 7 itemgroups, 69 items, 1 idioma
Itemgroups: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 52 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 8/3/20 - 1 formulario, 7 itemgroups, 69 items, 1 idioma
Itemgroups: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 8; 12; 16; 20; 28; 32; 36; 40; 44; 48 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 6/3/20 - 1 formulario, 7 itemgroups, 69 items, 1 idioma
Itemgroups: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Week 4 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status

- 2/3/20 - 1 formulario, 7 itemgroups, 69 items, 1 idioma
Itemgroups: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Unscheduled - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status; Ranibizumab Re-Injection

- 17/2/20 - 1 formulario, 8 itemgroups, 73 items, 1 idioma
Itemgroups: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status , Ranibizumab Re-Injection
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration NCT01134055 - Day 1 - Conjunctival Exam; Corneal Exam; Anterior Chamber Exam; Lens Opacity; Fundus Exam; Optical Coherence Tomography; Fundus photographs and fluorescein angiography status; Randomisation Number; Treatment Regimen; Investigational Product (Eye Drops) - First Dose Date/ Time, Dispensed, Administration

- 14/2/20 - 1 formulario, 12 itemgroups, 78 items, 1 idioma
Itemgroups: Conjunctival Exam , Corneal Exam , Anterior Chamber Exam , Lens Opacity , Fundus Exam , Optical Coherence Tomography , Fundus photographs and fluorescein angiography status , Randomisation Number, Treatment Regimen , Investigational Product (Eye Drops) - First Dose Date/ Time , Investigational Product (Eye Drops) - Dispensed, Eye Drop Administration
Study ID: 110852 Clinical Study ID: 110852 Study Title: MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01134055 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: pazopanib eye drops, ranibizumab intravitreal injection, placebo Trade Name: pazopanib, ranibizumab Study Indication: Macular Degeneration

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial